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ABSTRACT
The most important current anti-influenza weapons, vaccination and antiviral
drugs, can be rapidly rendered fully ineffective thanks to the virus’s high mutational rate,
which produces viruses exhibiting new antigenic properties and structural proteins
insensitive to the drug’s mechanism of action. One attractive alternative is to develop
drugs that modulate the activity of cellular systems either required for viral growth or
able to neutralize viral growth. Here we demonstrate that the cellular SUMOylation
system, a post-translational modification involving the conjugation of the Small
Ubiquitin-like MOdifier (SUMO) to specific protein targets using a Ubiquitin-like
enzymatic cascade, interacts closely with influenza virus during infection and therefore
provides new targets for the development of anti-influenza therapeutics targeting
cellular components.

Briefly, in vitro SUMOylation assays performed using in vitro

synthesized viral proteins demonstrated that most influenza viral proteins are readily
SUMOylated in vitro and therefore constitute potential SUMO targets. Transfection
experiments leading to the over-expression of specific viral proteins in the presence or
absence of various recombinant DNA constructs designed to modulate the activity of
the cellular SUMOylation system demonstrated that various viral proteins are also
SUMOylated when over-expressed in mammalian cells. Furthermore, experiments
performed using recombinant adenoviruses able to modulate the activity of the cellular
SUMOylation system demonstrated the SUMOylation of specific viral proteins during
influenza infection. Finally, this study characterizes the SUMOylation of the nonstuctural viral protein NS1A, the best SUMO target of all the viral proteins produced
during infection, explores some of the potential effects exerted by SUMOylation on the
vi

functions of this viral protein, and introduces the use of “artificial SUMO ligases” as an
innovative method to increase the SUMOylation of specific targets in the cell and
facilitate the characterization of the effects mediated by SUMOylation on protein
function. Collectively, our studies provide new insights into the virus-host interactions
established during influenza virus infections.
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CHAPTER 1: INTRODUCTION

Influenza is an acute contagious respiratory disease characterized by recurrent
annual epidemics and occasional but major worldwide pandemics. Despite all the efforts
and current available anti-influenza measures, influenza remains a global public health
concern due to the significant morbidity and mortality associated with it. The most
effective way to combat influenza is through vaccination, but this measure works
efficiently only when the circulating strains of influenza virus match perfectly the vaccine
strains. Natural mutations or antigenic drift, which occur frequently due to the highly
variable nature of this virus, produce a severe drawback against the efficacy of annual
vaccination, imposing the need to reformulate the vaccines every year depending on
the predicted circulating viral strains [1]. The other current anti-influenza weapons are
anti-viral drugs, which target structural components of the virus. To date there are only
two types of successful anti-viral drugs against influenza, but the selective pressure and
low fidelity of the viral polymerase render the virus prone to develop resistance against
all available antiviral drugs. In this context, there is an urgent need to develop novel
broad-spectrum tools against influenza virus that will work irrespective of the type, strain
or antigenic properties of the virus. In recent studies, the multifunctional Non-Structural
Protein 1 (NS1A) of influenza virus has emerged as an attractive target for antiviral drug
development [2, 3]. In this study, we explored how influenza A virus and its NonStructural Protein 1 (NS1A) interact with the cellular SUMOylation system, a posttranslational modification system known to regulate diverse biological processes but
previously unknown to have a link with influenza infection, with the ultimate goal of
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evaluating whether this cellular system may provide new targets for the development of
innovative therapies against influenza.
1.1 Influenza virus Biology:
Influenza virus is the prototype member of the family Orthomyxoviridae. It is an
enveloped RNA virus with a single-stranded, negative sense segmented genome. The
genome contains eight segments of viral RNA (vRNA) encoding 10-11 viral proteins, as
listed in Table 1 [4, 5]. Most of the RNA segments encode single proteins with the
exception of segments 7 and 8, and in some strains segment 2 as well, all of which
code for two different proteins. Out of the three types of Influenza viruses, (A, B and C),
Influenza A and B are important for human health. The antigenic determinants of the
virus are two surface glycoproteins, Haemagglutinin (HA) and Neuraminidase (NA),
which are embedded in the lipid membrane envelope. There are 16 HA and 9 NA
subtypes of the virus, which are capable of generating over 100 viral subtypes [6].
Table 1: RNA segments and encoded proteins of Influenza A virus:
RNA
Protein
Segment formed
PB2
1

Probable function
Polymerase component; Required for host cap binding

PB1

Polymerase component; Catalytic sub-unit of polymerase

PB1-F2

Induction of apoptosis

3

PA

4

HA

5

NP

Polymerase component; Active in genome replication; Required
for endonuclease activity
Antigenic determinant; Receptor binding and fusion with host
cells
Nucleoprotein; Viral assembly and RNA synthesis

6

NA

Antigenic determinant; Release of new viral particles

7

M1

Matrix protein; Viral assembly

2

2

M2
8

NS1A
NS2

Trans-membrane Ion channel; Release of vRNPs upon viral
envelope fusion to endocytic vesicle
Non-structural protein; Interferon antagonist; Inhibitor of host
antiviral responses; Modulator of mRNA splicing and translation
Nuclear export protein; Viral assembly

Influenza is unusual among RNA viruses by replicating its genome in the nucleus
of the host cell. During influenza infection, a virion attaches to sialic acid receptors in the
host cells via receptor binding sites in HA and enters the cells via receptor mediated
endocytosis to an endosome. The endosomal vesicle becomes increasingly acidic due
to the influx of H+ ions carried by lysosomal vesicles. Simultaneously the inside of the
viral particle also becomes more acidic, due to the transmembrane M2 protein, which
forms an ion channel in the viral envelope, thus allowing the influx of H+ ions. The acidic
environment within the viral particle promotes disruption of protein-protein interactions,
specifically the interaction of matrix protein M1 and nucleocapsids. In addition to that,
low pH also triggers a non-reversible conformational change of the structure of HA.
Altogether, these events lead to the fusion of the viral membrane with the endosomal
membrane resulting in the uncoating of the virus and release of vRNPs in the host
cytoplasm. From there the vRNPs translocate to the nucleus via nuclear pores. Once
inside the nucleus, the three sub-units of the polymerase complex (the RNA dependent
RNA Polymerase or RdRp), PB2, PB1 and PA, activate primary transcription leading to
the production of viral mRNA transcripts by a ‘cap snatching’ mechanism. Following
binding of PB2 subunit to the 5’ m7G caps of cellular mRNA transcripts, PA serves as
the viral endonuclease that steals the 5’ caps of cellular transcripts [7], which is then
used as the primer for the viral transcriptase, PB1 to mediate viral mRNA transcription
[8]. Transcription gives rise to eight primary transcripts, but the last two primary
3

transcripts (M and NS) each generate two alternative transcripts via alternative splicing.
The transcribed mRNAs migrate to the cytoplasm to be translated. After translation,
some viral proteins follow the secretory pathway (HA, NA, M2) to travel towards the cell
membrane while others are transported back to the nucleus (RdRp, NP, M1, NS1A,
NS2). Once the initial proteins are translated, they stimulate viral genome replication to
make new vRNAs, which happens later during infection as it requires encapsidation of
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replication intermediates mediated by NP. The binding of M1 to the nucleocapsid
formed by the tight association of NP and vRNA shuts down viral transcription and, with
the help of Nuclear Export Protein (NS2/NEP), the nucleocapsid migrates towards the
cell membrane. Meanwhile, the proteins following the secretory pathway (HA and NA)
undergo different modifications (e.g. Glycosylation) and along with M2 become
incorporated into the plasma membrane. M1 interacts both with nucleocapsids and
membrane-inserted HA or NA, driving the budding of new virions from the cell and the
release of new progeny virus upon sialic acid cleavage by NA [5, 6, 9, 10]. The
schematic diagram of Figure 1 illustrates the life cycle of influenza virus, from its initial
binding to the host cell to the ultimate release of infected virions from the cell.

1.2 Role of NS1A in Influenza A infection:
To counteract host defense mechanism viruses have evolved multiple strategies.
NS1A is the most important virulence factor encoded by Influenza A virus, and it is
known to exert multiple functions during infection to antagonize host immune responses
and to promote viral pathogenicity. This 26 kDa non-structural protein is one of the
major players during influenza infection as it antagonizes the interferon (IFN) response
and a plethora of cellular antiviral responses mounted upon viral infection [11]. It was
shown previously that mutant influenza viruses lacking NS1A gene can efficiently
replicate only in an IFN deficient system [12]. Additionally, some studies indicated that
NS1A serves as a major virulence factor for the highly pathogenic avian influenza virus
[13] and also for highly pathogenic human influenza viruses with pandemic potential
[14].
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The NS gene (8th viral genome segment) is the smallest genome segment of
influenza virus and it encodes for two mRNA splice variants, NS1A (NS1A) and NS2
(NEP). NS1A is expressed in very high levels and localized predominantly in the
nucleus. It has a variable length in different influenza viruses ranging from 230 to 237
amino acids [11].
Functionally NS1A can be divided in two distinct functional domains, the Nterminal RNA binding domain (RBD) (amino acids 1-73) and C-terminal Effector domain
(ED) (amino acids 74-230), which contains a disordered tail at its C-terminal end [11,
15]. The N-terminal RBD is mainly required for sequestration of dsRNA and direct
blocking the activity of two antiviral cytoplasmic proteins, Protein Kinase R (PKR) and
2’-5- Oligoadenylate Synthetase (OAS). Both of these proteins mediate host antiviral
response in a dsRNA dependent process. NS1A RBD outcompetes OAS for binding to
dsRNA and helps the virus to overcome the OAS/RNAse L antiviral mechanism of the
host, which is induced by IFN response. At the same time, RBD of NS1A also competes
with PKR for binding to dsRNA, thus preventing the auto-activation of PKR following
dsRNA binding that is required to shut off the host translational machinery and limit
production of viral proteins. Additionally the RBD is also essential for viral pathogenesis
due to its ability to suppress the RNAi response in the host cells [16]. The C-terminal ED
of NS1A is important for binding to a number of host factors such as a cellular protein
called Cleavage and Polyadenylation Specificity Factor (CPSF), which plays an
essential role in the processing the 3’ end of cellular mRNA transcripts. This interaction
inhibits

host

mRNA

production.

ED

also

binds

to

the

p85β

subunit

of

phosphatidylinositol 3-kinase (PI3K), which results in activation of PI3K signaling
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pathway and inhibition of apoptosis. Altogether the functions of NS1A lead to an
efficient influenza virus infection by overcoming host antiviral pathways [2, 15]. Besides
these key functions, NS1A is known to perform a plethora of other activities in influenza
infected cells as outlined in Figure 2.

Though in influenza virus infected cells NS1A predominantly localizes in the
nucleus, later during infection a significant proportion of the protein has also been
observed in the cytoplasm. Depending on the strain of influenza virus, NS1A may
contain one or two nuclear localization sequence(s) (NLS), and one nuclear export
sequence (NES). The first NLS (NLS1) of NS1A is a monopartite NLS that is highly
conserved, involving residues R35, R38 and K41. In contrast, the second NLS (NLS2) is
a bipartite NLS, which is absent in some viral strains and involves residues K219, R220,
R231 and R232 [11]. The cytoplasmic distribution of NS1A may be directed due to the
presence of a latent NES sequence located within residues 138-147 [17].
NS1A is known to be post-translationally modified by phosphorylation [18, 19, 20]
but the precise biological role of this modification is yet to be elucidated. In recent
7

studies, this protein also has been reported as the target for ISG15 [21, 22]. ISG15
modification of NS1A at a single residue (K41) is associated with loss of function of
NS1A thus affecting efficient viral replication, serving the purpose of antiviral action
mediated by the cells [21]. Finally, we recently reported that NS1A is also targeted by
cellular SUMOylation [23], as presented in this thesis.

1.3 The cellular SUMOylation system:
SUMOylation is a post-translational modification involving the covalent
conjugation of SUMO (Small Ubiquitin-like MOdifier) protein to lysine residue(s) in the
target protein. SUMO is synthesized as an immature precursor protein that is
proteolytically cleaved by SUMO-specific peptidases (SENP) to expose a C-terminal diglycine motif required for conjugation. Mature SUMO is activated by a heterodimeric E1
activating enzyme (SAE2/1) in an energy-consuming process. Subsequently, SUMO is
transferred to the E2 conjugating enzyme (Ubc9), which conjugates it to the target
protein. This step is facilitated by E3 ligases, which increase the specificity and speed of
the reaction but are not absolutely required for SUMOylation. SUMO is conjugated to
the target protein via an isopeptide bond formed between the carboxyl group of its Cterminal glycine residue and the epsilon amino group of a lysine residue in the target
protein. The modified lysine residues are frequently (but not always) located within the
consensus motif ΨKXE, where Ψ is a bulky hydrophobic residue, K is the target lysine
to be modified, X is any amino acid, and E is glutamic acid. In the final step,
Sentrin(SUMO)-specific proteases (SENPs) efficiently cleave the isopeptide bond
between SUMO and its target, rendering both available for subsequent rounds of
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modification, and making the pathway a reversible and dynamic process, as shown in
Figure 3 [24, 25, 26, 27].
SUMO proteins belong to the Ubiquitin-like Modifier (UBL) family although they
share less than 20% similarity with ubiquitin [24]. These proteins are approximately 10
kDa in size and as per our current knowledge, four mammalian SUMO isoforms have
been isolated so far, SUMO 1-4, [24]. Among the SUMO isoforms, mature forms of
9

SUMO2 and SUMO3 are 97% identical with each other, so they are commonly referred
as SUMO2/3 [24, 26], but they share only approximately 50% similarity with SUMO1
[24, 28]. Under normal physiological conditions SUMO1 conjugation seems most
predominant in the cell while SUMO2/3 remains mostly in the free non-conjugated form
[24, 29]; however, SUMO2/3 become heavily conjugated to target proteins under stress
conditions such as heat shock or hypoxia [26, 29]. The targets for SUMO1 and
SUMO2/3 appear to be distinct from each other, therefore suggesting different
functional roles for SUMO1 than SUMO2/3 [24, 27, 29, 30]. In general, SUMO
conjugation results from the addition of single SUMO moiety to the target proteins,
though SUMO2/3 is known to form poly-SUMO chains owing to the presence of an
internal SUMOylation site in SUMO2/3 [24, 27]. Most of all the SUMOylation that occurs
in the cell appears to take place in the nucleus, but increasing evidence supports the
idea that SUMOylation occurs ubiquitously throughout the normal cell [24], and it
exhibits effects on diverse biological functions ranging from signal transduction, subcellular localization, DNA damage repair, chromosome segregation, transcriptional
regulation, stress response and cell death [26, 31]. An emerging role for SUMOylation is
its potential relevance during infections with different viruses [31, 32, 33].

1.4 Development of an ‘Artificial SUMO Ligase’:
Though SUMOylation was first discovered more than a decade ago, the
identification and characterization of new SUMO targets remains challenging due to the
very low steady-state levels observed for the SUMOylated form of any given protein in
the cell. Except for a few exceptional SUMO targets, at any given time the SUMOylated
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form of a protein is only a very small fraction of the total amount of the protein present in
the cells (usually less than 1-5%) [34, 35]. Several studies have been performed with
the purpose of developing methods that will increase the level of SUMOylation of a
particular protein and therefore facilitate the analysis of the functional consequences of
SUMOylation. Among other methods, the development of SUMO-Ubc9 fusion [34] and
Ubc9 fusion directed SUMOylation (UFDS) [35] have proven quite advantageous in
analyzing the function of SUMOylation, though both of these methods have their own
caveats. As its name indicates, SUMO-Ubc9 fusions involve the over-expression by
transfection of a SUMO protein fused to Ubc9. This method has proven beneficial for
the identification of SUMOylated proteins, specifically of those containing a SUMO
interacting motif (SIM) [36], but it has very limited use for the analysis of the functional
consequence of SUMOylation for a particular target as it increases the global
SUMOylation of all proteins in the cell and decreases the specificity of the analysis. In
contrast, UFDS involves the fusion of Ubc9 to the specific protein under study, and
therefore it dramatically increases the SUMOylation of a particular protein, thus helping
its functional analysis [35, 36]. UFDS has proven useful even for the identification of
very weakly or transiently SUMOylated proteins [35] but it requires the formulation of an
Ubc9 fusion to the target protein and therefore restricts SUMOylation only to the fused
target protein and may alter its ability to establish specific protein interactions due to the
presence of Ubc9 as a structural component of the fusion protein.
In this study we report the development of the “artificial SUMO ligase” approach
that is based on the fusion of Ubc9, not to the SUMO target protein but to the interaction
domain from a known interacting partner, which can be a domain responsible for

11

dimerization in the case of proteins known to form dimers. The fusion here thereof
produced works as an artificial SUMO ligase by bringing Ubc9 in close proximity to the
SUMOylation site in the target protein and stabilizing its interaction with the target
protein, therefore specifically increasing the SUMOylation of the target protein. The
most relevant advantage over the other methods provided by the “artificial SUMO ligase
approach” is that it increases endogenous SUMOylation of a given protein to a
remarkable extent, therefore helping the functional analysis of the effect of SUMOylation
in a protein specific manner without increasing the global SUMOylation of the cell.

1.5 Viruses and SUMOylation:
SUMOylation is an important modulator of protein function, and provides a new
paradigm of virus-host interactions. Viruses normally interact with the SUMOylation
system either by modulating the system to enhance viral propagation or by utilizing the
system to secure the proper function of specific viral proteins [32, 33]. Alternatively, the
host also may utilize the SUMOylation system as a way to control viral infection. Even
though there are four known isofoms of SUMO identified in mammals, viruses appear to
interact mostly and preferably with SUMO1 [32]. Currently, there is very little evidence
demonstrating interactions of viral proteins with SUMO2/3 other than for Papilloma virus
E2 proteins (both human and bovine) [37] and human cytomegalovirus immediate-early
IE2 regulatory protein [38].
On the contrary, SUMO1 conjugation has shown the capability to modify a broad
range of viral proteins from different viruses such as the Human Cytomegalovirus
Immediate-early protein 1 (HCMV-IE1), for which SUMO1 conjugation of the IE1 protein
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appears required for the full activity of this protein [39], thus contributing to efficient viral
replication. The 86 kDa Immediate-early protein 2 of Human Cytomegalovirus (HCMVIE2) was also shown to be SUMO1 modified, and SUMO1 conjugation appears to be
important for IE2 mediated transactivation of two early viral promoters [40]. The Bovine
Papilloma virus E1 Protein (BPV-E1) also serves as a substrate for SUMO1 and for this
protein SUMO1 modification appears important for its helicase function and intranuclear
distribution, and nuclear export [41, 42]. For the Human T-cell leukemia virus Tax
oncoprotein, SUMO1 modification is required for its retention in the nuclear
compartment [43]. SUMOylation of the Adenovirus Type 5 early region 1B oncoprotein
(Ad5-E1B) is required for its transformation activity [44], and for the Hepatitis delta
antigen of the Hepatitis delta virus, SUMOylation modulates viral RNA synthesis [45].
The SUMOylation system also appears to exert some antiviral activities as
suggested by the fact that many viruses evolved different mechanisms to inactivate or
control the host’s SUMOylation system, as exemplified by the Gam1 protein, a viral
protein produced by an avian adenovirus. This protein promotes the ubiquitinylation of
the SUMO activating enzyme E1, thus leading to its proteasomal degradation and a
subsequent block in the system [46]. Similarly, Ebola Zaire virus hijacks the host
SUMOylation machinery to suppress innate immunity by SUMOylating IRF-7 [47].
Epstein-Barr virus and Human Cytomegalovirus block the SUMO modification of the
PML protein, thus leading to the disruption of the PML nuclear bodies, a step required to
induce lytic infections [48, 49]. Finally, the covalent attachment of SUMO1 to Human
immunodeficiency virus type 1 (HIV-1) Gag polyprotein (p6 domain) exemplifies
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utilization of SUMO modification by the host system against viral infection as
SUMOylation of p6 seems detrimental to HIV-1 replication [50].
Recently one genome-wide short interfering RNA (siRNA) screening in human
lung epithelial cells (A549) identified SUMOylation as one of the host machineries
required by influenza virus for effective viral multiplication [51]. Furthermore, a
combinational approach consisting of yeast two hybrid screenings along with genomewide expression profiling identified Ubc9 (UBE21), the SUMO conjugating enzyme, as a
direct interactor sor several influenza viral proteins [52]. Given that influenza virus is one
of the few RNA viruses that replicate inside the nucleus of the host cells and that most
of the influenza virus proteins bear conserved consensus SUMOylation motif(s) as
predicted by SUMOsp prediction software and summarized in Table 2, [53], it seems
possible that SUMOylation may play important roles during influenza virus infection.

1.6 Overall goal of this study:
This study pursued two major goals: 1) Determine whether any influenza viral
protein is SUMOylated during infection; and 2) Characterize the SUMOylation of one of
the viral SUMO targets identified. Throughout its execution, this study has demonstrated
a correlation between influenza virus infection and host cell SUMOylation system by
identifying several influenza viral proteins targeted by SUMOylation. Additionally, this
study has characterized the multifunctional NS1A protein of influenza virus as a bona
fide target for the SUMOylation system and identified the main SUMOylation sites in this
protein. Though the biological implication of SUMOylation for NS1A is yet to be fully
elucidated, an artificial SUMO ligase developed during this study to increase the
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SUMOylation of NS1A in a specific manner will greatly facilitate its functional analysis in
the future. Altogether this line of research provides new insights about the interaction of
influenza virus with the cellular SUMOylation system.
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CHAPTER 2: MATERIALS AND METHODS

2.1 Cells and viruses used: HEK293A cells (Invitrogen Corp., Carlsbad, CA), A549
cells (ATCC, Manassas, VA), and MDCK cells (ATCC) were maintained in 1x
Dulbecco’s Modified Essential Medium (DMEM) supplemented with high glucose, Lglutamine, sodium pyruvate, and 10% fetal bovine serum. The cells were maintained in
a 37oC incubator at 5% CO2. Influenza A/PR/8/34 (H1N1) and A/Vic/77 (H3N2) were a
gift from Dr. John M. Quarles (Dept. of Microbial and Molecular Pathogenesis, College
of Medicine, Texas A&M Health Science Center) and were propagated in MDCK cells at
MOI 0.001 using 1x DMEM supplemented with 0.2% bovine serum albumin and 2
μg/mL TPCK-treated trypsin (Worthington Biochemical Corp., Lakewook, NJ).
2.2 Plasmids: The individual expression plasmids coding viral genes were constructed
following the method previously demonstrated by Hoffmann et al. [54]. All eight viral
genes from Influenza A/PR/8/34 (PB2, PB1, PA, HA, NP, NA, M & NS) were cloned by
reverse transcription-PCR (RT-PCR) using first a UNI-12 primer targeting the 12
conserved nucleotides at 3’ end of extracted viral RNA from infected supernatants using
MagMAX™ viral RNA isolation kit (Applied Biosystems, Foster City, CA), and
subsequently with PCR reactions using segment specific forward and reverse primers to
amplify cDNA copies of each gene segment of influenza virus and inserted into
pcDNA3.1 mammalian expression vector (Invitrogen Corp., Carlsbad, CA) following InFusion™ Dry-Down PCR Cloning method (Clontech, Mountain View, CA).
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2.3 In-vitro SUMOylation assays: In vitro sumoylation assays were performed as
reported in earlier studies [55]. All different viral proteins were synthesized from
maxipreped

DNA

and

labeled

with

35

S-Methionine,

using

a

coupled

transcription/translation rabbit reticulocyte system under the control of the T7 promoter
(Promega Corp., Madison, WI). Subsequently, the

35

S-labeled protein products were

incubated at 30°C for 90 minutes in the presence of either, 1 µg of the purified catalytic
domain of the yeast de-SUMOylating enzyme Ulp1, or a mix of 1.5 µg purified SUMO1,
280 ng E1 activating (SAE2/1) and 1 µg E2 conjugating (Ubc9) enzymes of
SUMOylation. To confirm the identity of any extra higher molecular weight band
observed in the latter reaction as a SUMOylated form of the target protein, an additional
sample was incubated with a mix of purified SUMO1 and the E1 and E2 SUMOylation
enzymes in each case, but 30 minutes after the beginning of the reaction, 1 µg of Ulp1
was added to the sample. All reactions were performed in the presence of a previously
described SUMOylation reaction buffer containing 50 mM Tris pH 8.0, 5 mM MgCl2, 5
mM ATP, and 0.5 mM DTT [55]. The reactions were stopped by the addition of 4X
sample buffers (50mM Tris pH 6.8, 10% glycerol, 4% SDS, 0.01% bromophenol blue,
2% β-mercaptoethanol). The samples were then subjected to be resolved in 10% SDSPAGE gels and developed by autoradiography. The recombinant construct for the
expression and purification of Ulp1403-621 was kindly provided by Dr. Christopher D.
Lima (Structural Biology Program, Sloan-Kettering Institute, 1275 York Avenue, New
York, NY).
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2.4 Transient transfections and transductions with Recombinant Adenoviruses:
HEK293A cells were seeded at the density of 105 cells/well in 24 well plate, next day
transfected with desired combinations of plasmids using TransIT®-LT1 (Mirus Bio LLC,
Madison, WI) according to the manufacturer’s recommendations and cell extracts were
collected either following 24 hours post-transfection when further analyzed by
immublotting or 48 hours post-transfection when analyzed for affinity purifications.
Transductions with recombinant adenoviruses as described in our previous report [23]
were performed in A549 cells at a multiplicity of infection (MOI) of 100, using fully
confluent cell cultures. The transduced cells were used for the desired experimental
procedure 48 h post-transduction to allow appropriate expression of the adenovirusencoded transgenes.

2.5 Affinity Purification of SUMOylated proteins: For the affinity purification of all
SUMOylated proteins, cells grown and treated as necessary in 6 well plates were
collected in 300 µL of denaturing buffer (8 M Urea, 100 mM NaH2PO4, 10 mM Tris,
0.2% Triton X-100, 20 mM NEM, pH 8.0), and the resulting cell extract was sonicated to
breakdown the chromosomal DNA and decrease the viscosity of the sample. A 50 µL
aliquot of the resulting extract was mixed with an equal volume of 4x sample buffer for
direct immunoblot analysis of Total Cell Extract (TCE). The remaining 250 µL were
diluted with 3,750 µL of dilution buffer (100 mM NaH2PO4, 10 mM Tris, 0.2% Triton X100, 20 mM NEM, pH 8.0), and incubated with 100 µL (wet volume) of S-Protein
agarose beads (Novagen, EMD Biosciences Inc.) for 16 h at 4oC. The diluted cell
extract-bead mixture was poured over an empty chromatography column and the
packed beads were washed with 30 mL of ice-cold 1x PBS, and the bound proteins
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were eluted by the addition of 100 µL of 4x sample buffer, to be analyzed by
immunoblotting in 10% SDS-PAGE gels.

2.6 Immunoblot analysis: Monolayers of cells previously treated by transfection,
transduction and/or infection as needed were lysed in 2X sample buffer and following
breakage of chromosomal DNA using using a 29½ gauge needle were heated for 3 min
at 100°C after addition of 10% β-mercaptoethanol. The samples were resolved by 10%
SDS-PAGE gels, using either pre-made PAGEgel™ gels (PAGEgel Inc., San Diego,
CA) or SDS-PAGE gels made in-house. The resolved proteins were transferred onto a
PVDF Immobilon™-P membranes (Millipore Corp, Bedford, MA) and blocked with 3%
non-fat milk in 1X PBS with 0.5% Tween for 30 min. at room temperature. After blocking
the membrane, in each case the membrane was incubated with primary antibody
overnight at 4°C and subsequently incubated for 1 hr. at room temperature with antirabbit or anti-mouse secondary antibody. The membranes were developed using the
Immobilon™ Western HRP Substrate system (Millipore). In most experiments the
membranes were re-used a minimum of three times. Before re-use, the Immobilon™
membranes were stripped by incubation in boiling stripping buffer (1% SDS and 0.2% βmercaptoethanol) for 10 min, and washed five times with 1x PBS supplemented with
0.05% Tween 20.
The following primary and secondary antibodies were used in this study
for western blotting: anti-T7 tag® mouse MAb (Novagen, EMD Biosciences Inc., San
Diego, CA) at 1:5,000 dilution; anti-NP mouse MAb clone AA5H (Meridian Life Science,
Inc., Memphis, TN) at 1:2,500 dilution; anti-M1 mouse MAb clone GA2B (Meridian Life
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Science, Inc.) at 1:5,000 dilution; anti-SUMO1 rabbit MAb Y299 (Epitomics Inc.,
Burlingame, CA) at 1:5,000 dilution; anti-PB1 goat polyclonal antibody vK-20 (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) at 1:2,500 dilution; anti-PB2 amino terminus
mouse MAb clone 170-3C12 (obtained through the NIH Biodefense and Emerging
Infections Research Resources Repository, NIAID, NIH) at 1:1,000 dilution; anti-NS1A
mouse MAb, clone NS1A-1A7 (BEI Resources) at 1:1,000 dilution; anti-Ubc9 rabbit
MAb EP2938Y (Epitomics Inc.) at 1:5,000 dilution; anti-GAPDH mouse MAb 2D4A7
(Santa Cruz Biotechnology, Inc.) at 1:5,000 dilution; anti-SUMO2 rabbit PAb (Invitrogen)
at 1:5,000 dilution: anti-mouse IgG goat polyclonal antibody HRP-conjugated (Santa
Cruz Biotechnology, Inc.) for detection of all mouse MAbs; anti-rabbit IgG goat
polyclonal antibody HRP-conjugated (Santa Cruz Biotechnology, Inc.) for detection of all
rabbit MAbs; and anti-goat IgG donkey polyclonal antibody HRP-conjugated (Santa
Cruz Biotechnology, Inc.) for detection of all goat polyclonal antibodies.

2.7 SUMOylation site prediction: The SUMOylation site predictions for all different
protein components of Influenza virus were done using SUMOsp 2.0 software [53],
where the cut-off value for predictions was set to medium except otherwise indicated.
Two prediction softwares, SUMOsp2.0 [53] and SUMOplotTM [56], were used for
identifying potential SUMOylation site(s) in NS1A.

2.8 Site-directed mutagenesis: A T7 tag (MASMTGGQQMG) was introduced at the Nterminus of NS1A protein for easier detection using Phusion® Site-Directed
Mutagenesis Kit (Finnzymes, Woburn, MA) following manufacturer’s protocol. For
mutagenesis study to map the SUMOylation site in NS1A, same kit (Finnzymes) was
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used for generating the SUMOylation deficient mutant clones and so for generation of
T7 tagged NS2 construct.
2.9 Immunofluorescence Analysis: For immunofluorescence analyses, cells were
fixed with 4% paraformaldehyde and sequentially permeablized with 100% methanol
and 0.5% Triton X-100 in 1x PBS for 10 min each. Upon permeabilization, the cells
were incubated in blocking solution (1x PBS supplemented with 3% goat serum)
followed by incubation with primary antibodies. Following primary antibodies were used
for immunofluorescence: anti-T7 tag® mouse MAb (Novagen) at 1:2,000 dilution, antiUbc9 rabbit MAb EP2938Y (Epitomics Inc.) at 1:1,000 dilution and anti-NS1A mouse
MAb (BEI Resources) at 1:1,000 dilution. Alexa Fluor® 488 goat anti-mouse (highly
cross-absorbed) and Alexa Fluor® 594 goat anti-rabbit (highly cross-absorbed) (both
from Invitrogen Corp.) were used as the secondary antibodies. All procedures after the
addition of the secondary antibody were executed in the dark. Images were captured
using a Nikon TS-100 fluorescence microscope and a Nikon DS-2M Color Digital
Camera.
2.10 Cycloheximide treatment: For cycloheximide treatment, HEK293A cells were
seeded at the density of 105 cells/well in 24 well plate, transfected with WT T7NS1A or
T7NS1AK70A/K219A, and 24 hours post-transfection treated with 100 μg/ml
cycloheximide (Sigma-Aldrich Corp.,St. Louis, MO) for the indicated time periods, after
which the cell lysates were collected in 2X sample buffer and prepared for
immunoblotting as indicated above.
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CHAPTER 3: RESULTS AND DISCUSSION

3.1 All Influenza viral proteins contain conserved SUMOylation site(s):
In silico sequence analysis of all protein components of influenza virus by
prediction software SUMOsp 2.0 interestingly revealed the presence of one or more
consensus motif(s) in the sequences of all influenza viral proteins tested as listed below
in Table 2. Even though there are plenty of proteins reported to be SUMOylated at
lysine residues lacking the SUMO consensus motif, and proteins containing the SUMO
consensus motif are not necessarily SUMO targets [29], this analysis suggested that
there may be some connection between the cellular SUMOylation system and influenza
virus.

Table 2: Predicted SUMOylation site(s) in different influenza viral proteins (predicted by
SUMOsp 2.0):
Protein

Position

Peptide sequence

Type

PB2

189

TKEKKEE

Type: Non-consensus

190

KEKKEEL

Type: Non-consensus

339

SSVKREE

Type: Ψ-K-X-E

699

ILGKEDK

Type: Non-consensus

718

NLAKGEK

Type: Ψ-K-X-E

176

SMNKEEM

Type: Non-consensus

612

VCLKWEL

Type: Ψ-K-X-E

736

GRIKKEE

Type: Ψ-K-X-E

737

RIKKEEF

Type: Non-consensus

757

RRQK***

Type: Non-consensus

29

EDLKIET

Type: Ψ-K-X-E

139

NKIKSEK

Type: Ψ-K-X-E

PB1

PA

22

158

MATKADY

Type: Non-consensus

361

KNMKKTS

Type: Non-consensus

521

DGVKLES

Type: Ψ-K-X-E

7

QGTKRSY

Type: Non-consensus

113

LYDKEEI

Type: Non-consensus

NA

242

KIFKIEK

Type: Ψ-K-X-E

M1

21

GPLKAEI

Type: Ψ-K-X-E

104

RKLKREI

Type: Ψ-K-X-E

187

TTAKAME

Type: Non-consensus

252

QRFK***

Type: Non-consensus

70

RILKEES

Type: Ψ-K-X-E

219

PKQKREM

Type: Non-consensus

18

RMSKMQL

Type: Non-consensus

HA
‡

NP

NS1A
NS2(NEP)

‡

‡ The cut-off value for SUMOylation site prediction for these proteins was set to LOW, for all others it was MEDIUM.

3.2 Influenza infection increases overall cellular SUMOylation levels:
To evaluate whether influenza virus

infection affected overall cellular

SUMOylation following influenza infection in a cell culture system, MDCK cells were
infected at different infectious viral particles to cell number ratios (a proportion referred
to as Multiplicity of Infection, or MOI), using two influenza viral strains, A/PR/8/34 H1N1
and A/Vic/77 H3N2. Unfractionated (total) cell extracts of the infected cells were
collected 15 hrs. post-infection (p.i.) and evaluated by immunoblotting using antiSUMO1 antibody. An increase in overall SUMOylation (SUMO1 conjugation) following
influenza virus infection was observed, as demonstrated by the appearance of new
intermediate molecular weight bands and an increase in the intensity of the high
molecular weight SUMO bands upon viral infection [Figure 4A]. However, no significant
differences were observed in the steady-state levels of the SUMO E2 conjugating
enzyme Ubc9 upon viral infection [Figure 4B]. Anti- NS1A immunoblot analysis
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confirmed the expected increase in the expression of viral proteins upon increased MOI
[Figure 4C]. Altogether, these observations strongly support an interaction between the
cellular SUMOylation system and Influenza A virus.

3.3 Most influenza viral proteins are SUMOylated in vitro:
The in vitro SUMOylation assay is a quick and convenient screening method to
determine if any given protein is modified by SUMOylation. Following the procedure
described by Rosas-Acosta et al. [55], and using a set of cDNA expression constructs
spanning the full array of influenza virus genes derived from our laboratory strain of
Influenza A/PR/8/34 H1N1 (cloned by the author), we tested the SUMOylation potential
of most of the virus-encoded proteins. In these assays we found that most of the
influenza viral proteins, including the three sub-units of the viral RNA polymerase (PB2,
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PB1, PA), and the viral proteins HA, NP, M1 and NS1A are all very efficiently
SUMOylated in vitro. As shown in Figure 5A, the appearance of one or more higher
molecular weight form(s) in the middle lane for most of the in vitro translated and
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S-

labeled proteins in presence of all SUMO components (indicated by arrows), and its
disappearance in presence of all SUMO components following incubation with the deconjugating enzyme Ulp1, conclusively demonstrated that the higher molecular weight
form(s) observed correspond to SUMOylated forms of the proteins being tested, and
that most of the viral proteins, at least seven out of the eight protein tested, served as
targets for cellular SUMOylation system. Western blot analysis with anti-SUMO1
antibody [Figure 5B] validated the findings, as conjugated higher molecular weight
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forms of SUMO1 were observed in the middle lanes of each of the groups in the
absence of Ulp1, and the deconjugated free form of SUMO1 was the main product
observed following Ulp1 incubation. Altogether, the data indicates that most of the
influenza virus proteins of Influenza A/PR/8/34 H1N1 are subjected to modification by
SUMO1. In this experiment, C/EBP-β1, a well characterized SUMO target was used as
positive control [57].

3.4 Few viral proteins are SUMOylated when over-expressed by transfection:
In a recent report, we demonstrated that dicistronic constructs containing the
SUMO1 or SUMO3 ORF followed by the internal ribosomal entry site sequence of the
Endomyocarditis virus (EMCV) and the Ubc9 ORF, both under the control of the
cytomegalovirus promoter, were able to induce robust SUMOylation, when transfected
in mammalian cells and therefore provide an efficient method to identify SUMO targets
in a cell culture system [23]. Following co-transfection in HEK293A cells with (+) and
without (-) the combinations of indicated plasmids including the dicistronic plasmid for
SUMO1 (referred as Dual S1/I/U), and the purification of SUMOylated proteins by
affinity chromatography on S-protein agarose beads, owing to the presence of an S-tag
at the N-terminus of the SUMO1 encoded in the dicistronic SUMO1 construct, we have
found that at least three influenza virus proteins are targeted by the cellular
SUMOylation system in a mammalian cell culture model [Figure 6]. Analysis of total cell
extracts (TCE) [Figure 6A & B] by western blot revealed the presence of a high
molecular weight form for both T7 tagged NS1A and M1 [Figure 6A, diagonal arrows,
lanes 5 and 17, respectively], when the indicated protein was over-expressed along with
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exogenous SUMO1 and Ubc9 (co-transfected with Dual S1/I/U). The disappearance of
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the higher molecular weight form of the protein when co-expressed with the
combinationof SUMO1 and mammalian de-SUMOylating enzyme SENP1, conclusively
demonstrated that the extra higher molecular weight forms observed in the indicated
lanes truly correspond to SUMOylated forms of T7NS1A and M1. Total Cell Extracts
(TCE) analysis did not reveal presence of any similar higher molecular weight form of
NP but longer exposure of the membrane was hindered by presence of other crossreactive bands. The global effects on cellular SUMOylation produced by co-expression
of SUMO1 and Unc9 in the presence and absence of the de-SUMOylating enzyme
SEMP1 are clearly evident on the SUMO-immunoblot presented in Figure 6B.
The protein profile obtained upon purification on the S-protein beads
demonstrated that T7NS1A and NP are authentic SUMO targets in vivo. In the presence
of Dual S1/I/U, a significant proportion of unmodified T7NS1A was purified on the Sbeads [Figure 6C, asterisk, lane 4], along with a higher molecular weight form
corresponding to the molecular weight of SUMOylated T7NS1A [Figure 6C, diagonal
arrow, lane 4]. The absence of the higher molecular weight form of the protein in the
presence of excess SENP1, associated with increased de-SUMOylating activity [lane 5],
further supported the conclusion that T7NS1A is efficiently SUMOylated in a cell culture
system. The presence of unmodified T7NS1A even after affinity purification may be a
result of the dimerization of NS1A, thus allowing the purification of unmodified forms
along with the modified protein. Alternatively it could be due to the co-purification of deSUMOylating enzymes on the beads which become activated during the last washes or
during the last stages of sample processing in preparation for SDS-PAGE. Interestingly,
an extra band between the SUMO-modified and unmodified forms of T7NS1A were
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observed, specifically at around ~37 kD. This band might correspond to SUMOylated
NS2 (NEP), which is the splice variant of NS1A, as the molecular weight of the band fits
nicely with the predicted size of the SUMOylated form of NS2. Subsequence
experiments have provided conclusive support to this conjecture.
Similar results were observed for NP, for which a higher molecular weight form,
visible in presence of Dual S1/I/U [diagonal arrow, lane 9], disappeared in presence of
SENP1, thus indicating that NP is also targeted by the cellular SUMOylation system.
Surprisingly, no higher molecular weight form of M1 was visible following S-beads
purification [Figure 6C, lane 14], although it was obvious in the immunoblot analysis of
the TCE. However, the presence of unmodified form of M1 in presence of Dual S1/I/U
[asterisk, lane 14], but not in M1 alone [lane 13] or in presence of excess SENP1 [lane
15], indicated that M1 is also likely to be SUMOylated in cell culture, although the
intensity of the SUMO modified and S-beads purified form of M1 may not be as intense
as compared to others. Figure 6D showed the global profile of the SUMO1 conjugation
and de-conjugation profile and fits nicely the expected profile.

3.5 Several viral proteins are also SUMOylated following infection:
To determine whether any of the influenza virus proteins is SUMOylated during
infection, A549 cells were transduced with recombinant adenoviruses carrying either the
dicistronic SUMO1 construct (AdV-Dual S1/I/U) or a mutated version of the construct
containing a deletion of the two C-terminal glycine residues in SUMO1(AdV-Dual
S1ΔGG/I/U). The terminal di-glycine motif is essential for SUMO conjugation, so
deletion of the di-glycine motif in AdV-Dual S1ΔGG/I/U renders the over-expressed
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SUMO1 non-conjugatable but still capable of binding to Ubc9, therefore producing a
block in the SUMOylation cascade. The latter construct (AdV-Dual S1ΔGG/I/U) served
as ideal negative control for our study. 48 hours post-transduction, the cells were
infected with either of two strains of Influenza A virus, A/PR/8/34 H1N1 or A/Vic/77
H3N2 and samples were collected 15 hours post-infection in a denaturing buffer
containing 8M urea as described previously. TCE were subjected to SDS-PAGE and
Western Blotting analysis and the SUMO-modified proteins were purified on S-protein
agarose beads and analyzed separately by SDS-PAGE and Western Blotting.
As shown in Figure 7, two of the viral proteins (M1 and NS1A) are SUMOylated
during viral infection, two (NP and PB1) are likely to be modified by SUMO following
infection, and one (PB2) seems not to be modified by SUMO. Importantly, all viral
proteins were easily detected in the TCE, but higher molecular weight forms suggestive
of SUMO-modification were not observed for any of the viral proteins in samples
infected with A/PR/8/34 H1N1 or A/Vic/77 H3N2. In sharp contrast, the S-beads purified
samples showed clear evidence of SUMOylation for M1 and NS1A. From the S-beads
profile in Figure 7D, it is evident that the M1 protein from both strains of Influenza A
virus tested are equally targeted by the cellular SUMOylation system, as implied by the
profile observed of SUMO modified M1 bands [Figure 7D, lanes 8 & 11, diagonal
arrows]. The absence of the high molecular weight bands in lanes with over-expressed
but non-conjugatable SUMO1 (AdV-Dual S1ΔGG/I/U) [Figure 7D, lanes 9 & 12]
demonstrated that the bands observed are SUMOylated forms of M1. Along with the
SUMOylated form of M1, a significant proportion of unmodified M1 protein was also copurified from S-beads purification, but the absence of any unmodified form of M1 in
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lanes transduced with AdV-Dual S1ΔGG/I/U [Figure 7D, lanes 9 & 12], indicated that
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the purification of the unmodified form of the protein in S-beads was likely due to the copurification of de-SUMOylating enzymes in the S-protein beads. Similar results were
observed with NS1A also, where SUMO modified forms of NS1A were observed from
samples infected with both strains of Influenza virus [Figure 7E, lanes 8 & 11, diagonal
arrows], though the modified higher molecular weight form of NS1A was much more
prominent in the sample infected with A/PR/8/34 H1N1, than in the sample infected with
the A/Vic/77 H3N2. Along with the modified form, significant amount of unmodified
NS1A was also detected when transduced with AdV-Dual S1/I/U but not with AdV-Dual
S1ΔGG/I/U, indicating that the potential co-purification of cellular de-SUMOylating
enzymes.
Other than the influenza viral proteins discussed above, which are clearly
SUMOylated during infection, PB1 and NP are the other proteins that are likely to be
targeted also by the cellular SUMOylation system. Although both the TCE and S-protein
beads purified protein profiles for either protein did not reveal any high molecular weight
forms suggestive of SUMOylation, the co-purification of the unmodified form of the
protein in cells transduced with AdV-Dual S1/I/U but not in cells transduced with AdVDual S1ΔGG/I/U [Figure 7A and 7C, S-protein beads profile], indicated that SUMO
conjugation was responsible for the co-purification of the unmodified form of the
proteins. Given that at any time point the proportion of the SUMO modified form of any
protein is significantly less than the unmodified form, it was very likely that the SUMO
modified form was below the detection level for the antibody. Altogether the data
indicated that PB1 and NP are also likely to be authentic SUMO targets.
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Interestingly, although PB2 was modified by SUMO1 in the in vitro SUMOylation
assay, we observed no indication that it was modified during infection, as neither the
modified nor the unmodified forms of the protein were detected on the S-protein beads
[Figure 7B]. The TCE profile confirmed that the protein was present in the samples
infected with both strains, thereby suggesting that PB2 is not targeted by SUMO1
modification during viral infection. The western blot profile obtained with the antiSUMO1 antibody [Figure 7F] followed the expected profile, showing a substantial
increase in high molecular weight SUMO1 conjugates in samples transduced with the
AdV-Dual S1/I/U but not with the AdV-Dual S1ΔGG/I/U.

3.6 NS1A is modified even with endogenous SUMOylation:
Among all the viral proteins tested, NS1A seemed the best SUMO target. To
determine whether NS1A is modified by endogenous SUMOylation also, another set of
transient transfection experiment was performed with over-expressed T7NS1A in
absence (-) and presence (+) of exogenous SUMO1, with (+) or without (-) SENP1. As
shown in Figure 8, even in absence of extra copies of SUMO1, an extra higher
molecular weight band of T7NS1A was observed [Figure 8A, lane 2, diagonal arrow],
which disappeared when SENP1 was over-expressed [Figure 8A, lane 3], indicating that
the band observed is T7NS1A modified by endogenous SUMO. In the presence of
exogenous SUMO1, an extra higher molecular weight band was evident [Figure 8A,
lane 4, diagonal arrow], which was shifted slightly higher than the band observed in lane
2. The disappearance of the latter band in the presence of SENP1 conclusively
indicates that T7NS1A is SUMO modified, this time with the exogenous SUMO1. The
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difference in molecular weight of both SUMO1 modified bands of T7NS1A is due to the
presence of a dual tag (His and S tag) at the N-terminus of the protein encoded by the
Dual SUMO1 expression construct (Dual S1/I/U) [23], which was used to over-express
SUMO1. As shown in Figure 8B, there was a significant difference in global SUMO1
conjugation between endogenous and over-expressed SUMO1 [Figure B, lane 2 and
lane 4]. Remarkably, in spite of the substantially limiting levels of global SUMOylation
observed in the absence of over-expressed SUMO, T7NS1A was still efficiently
SUMOylated, emphasizing again a possible role of SUMOylation during influenza virus
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infection. Figure 8C showed the cellular levels of the endogenous and exogenous Ubc9;
the slight shift in molecular weight observed in over-expressed Ubc9 resulted from the
presence of an HA tag at the N-terminus of the protein. Figure 8D referred to the
loading control of the experiment, the house keeping gene GAPDH. Altogether, the data
conclusively demonstrated that NS1A is a bona fide target of the cellular SUMOylation
system, being modified with endogenous SUMO in a mammalian cell culture system.

3.7 NS1A is modified not only by SUMO1, but also with SUMO2/3:
Some known SUMO targets are preferentially SUMOylated with either SUMO1 or
SUMO2/3, whereas others seem to be equally SUMOylated with both main SUMO
types [26, 58]. To determine whether NS1A is preferentially conjugated to SUMO1 or
SUMO2/3, similar transfection experiments were performed including a dicistronic
construct coding for SUMO3 and Ubc9 (Dual S3/I/U) in HEK293A cells. The data
obtained [Figure 9] demonstrated that in the presence of exogenous SUMO1, an extra
higher molecular weight band was evident [Figure 9A, lane 4], corresponding to SUMO1
modified T7NS1A, as described earlier. Surprisingly, such extra higher molecular weight
band was also observed in presence of exogenous SUMO3 [Figure 9A, lane 9] and in
this case the band also disappeared in the presence of excess deconjugating enzyme,
SENP1 [Figure 9A, lane 10], confirming its identity as a SUMOylated form of T7NS1A.
The overall profile of SUMO2/3 conjugation and de-conjugation followed the expected
profile as detected with SUMO2 antibody [59] [Figure 9B, lanes 5-10]. The anti-SUMO1
immunoblot presented in Figure 9C validated the overall conjugation and de-conjugation
pattern of SUMO1, and in Figure 9D GAPDH level confirmed equal loading in all the
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samples. Altogether, this finding suggested that NS1A has the potential to be equally
conjugated by both SUMO1 and SUMO2/3.

3.8 Prediction of potential SUMOylation site(s) in NS1A:
To generate a non-SUMOylatable form of NS1A, it was important to first identify
the lysine residue(s) on which NS1A is SUMOylated and then mutate the predicted
lysine residues to alanine using a site-directed mutagenesis approach. The probable
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SUMOylation site(s) in NS1A were predicted using several SUMOylation prediction
softwares. As shown in Table 3, both SUMO prediction softwares used (SUMOplotTM
and SUMOsp 2.0) [53, 56], identified lysine residues K70 and K219 as potential
SUMOylation sites in NS1A. Out of the two predicted lysine residues, K70 followed the
consensus motif for SUMOylation (Ψ-K-X-E) whereas K219 did not.
Table 3: Predicted SUMOylation sites in NS1A (using SUMOplotTM and SUMOsp 2.0):
Prediction software

Position of lysine residue

Peptide sequence

SUMOplotTM

K70

IVERI LKEE SDEAL

K219

PLTPK QKRE MAGTI

K70

RILKEES

K219

PKQKREM

SUMOsp 2.0

However, current prediction softwares were designed based on limited available
data and there are several proteins that contain a perfect SUMO consensus motif, but
still are not SUMOylated. Similarly, there are several SUMO target proteins that are
SUMOylated at sites located outside of a consensus motif [29]. So, the computationally
predicted site still needed to be confirmed experimentally.

3.9 Mapping of SUMOylation site(s) in NS1A:
To confirm the site of SUMOylation in NS1A, point mutants bearing K to A
substitutions of the residues previously predicted as potential SUMOylation sites were
generated. To this end, three mutants, namely T7NS1A-K70A, T7NS1A-K219A and
T7NS1A-K70AK219A were generated. As indicated their names, the first two contained
single K to A amino acid substitutions, whereas the third contained two K to A
substitutions. To analyze the effect of the point mutations on NS1A SUMOylation,
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HEK293A cells were transiently transfected with the T7NS1A mutants along with Dual
S1/I/U, in presence (+) or absence (-) of SENP1, or an expression plasmid for a nondeSUMOylatable form of SUMO1 and Ubc9 (Dual SUMO1Q94P/I/U). At 24 hours posttransfection, the cell lysates were collected in 2X sample buffer and the SUMOylatability
of the mutants was evaluated by SDS-PAGE and Western Blotting and compared to the
parental T7NS1A (hereafter referred as WT T7NS1A).
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As shown in Figure 10, when co-transfected with Dual S1/I/U, the T7NS1A-K70A
mutant showed a small decrease in its ability to be SUMOylated [Figure 10A, Lane 6],
whereas the T7NS1A-K219A mutant showed a significant decrease in SUMOylation
[Figure 10A, Lane 9], compared to the level of SUMOylation observed in WT T7NS1A
[Figure 10A, Lane 3]. A double mutant containing K to A mutations in both sites
(T7NS1A-K70AK219A) was almost not SUMOylated at all [Figure 10A, Lane 12].
Simultaneous

analysis

performed

with

non-deSUMOylatable

construct

Dual

SUMO1Q94P validated our observations [Figure 10A, Compare Lanes 8, 11 and 14
from Lane 5]. The immunoblot profile obtained with the anti-SUMO1 antibody [Figure
10B], showed the expected conjugation pattern including the de-conjugation profile
conferred by the over-expression of SENP1. In the same experiment, GAPDH was used
as the loading control [Figure 10C] and it indicated that similar levels of protein were
loaded for all the different samples. Therefore, the data presented here identified K219
as the primary SUMO1-SUMOylation site in NS1A, while K70 appeared to act as a
secondary SUMOylation site.

3.10 SUMO2/3 conjugation of NS1A occurs through the same residue as SUMO1:
In order to verify if SUMO2/3 conjugation happens through the same residues as
SUMO1, or it follows any other SUMOylation site(s), another set of transient transfection
experiments were performed in HEK293A cells with the deconjugatable dicistronic
construct expressing SUMO3 and Ubc9 (Dual S3/I/9), in the absence (-) or presence (+)
of the deconjugating enzyme SENP1, or a non-deconjugatable dicistronic construct for
SUMO3 (Dual S3Q89P/I/U). It was observed that the pattern of SUMOylation of
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T7NS1A with SUMO3 was very similar to the SUMOylation pattern observed with
SUMO1, as revealed in Figure 11. Again, the T7NS1A-K70A mutant showed a small
decrease in its ability to be SUMOylated by SUMO3 [Figure 11A, Lane 6], while the
T7NS1A-K219A mutant showed a significant decrease in SUMOylation [Figure 11A,
Lane 9], compared to the level of SUMO3 SUMOylation observed in WT T7NS1A
[Figure 11A, Lane 3]. Also, the double mutant (T7NS1A-K70AK219A) was almost
lacking in its ability to be SUMOylated. Analysis performed with the non-deconjugatable
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mutant, Dual S3Q89P/I/U, further confirmed these observations. Figure 11B
represented the overall conjugation and de-conjugation pattern observed with SUMO2
antibody, while the GAPDH level in Figure 11C confirmed equal loading in all samples.
Altogether, these findings suggested that the same lysine residues were targeted by
SUMO1 and SUMO2/3 conjugation.

3.11 SUMOylation does not seem to affect sub-cellular distribution of NS1A
following transfection:
SUMOylation is known to alter the sub-cellular localization of some of its targets
[60]. In order to assess if SUMOylation plays any role in the sub-cellular distribution of
NS1A, the effect of SUMOylation on the localization of NS1A was evaluated using
different SUMOylation-deficient mutants of T7NS1A. To monitor any alteration in
localization, HEK293A cells were seeded and 24 hours later co-transfected with Dual
S1/I/U and WT T7NS1A or the different SUMOylation-deficient mutants of T7NS1A
(K70A, K219A, K70AK219A). At 24 hours post-transfection, the cells were fixed and
analyzed by immunofluorescence using a mouse monoclonal antibody against T7 and
rabbit monoclonal antibody against Ubc9 as primary antibodies, and Alexa 488 Goat
anti-mouse and Alexa 594 Goat anti-rabbit both highly cross-absorbed as secondary
antibodies.
As shown in Figure 12, it was apparent that there was no significant change in
the localization of the SUMOylation deficient mutants of T7NS1A as compared to WT
T7NS1A. As evidenced in the merged images, the localization of SUMOylation deficient
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mutants (K70A, K219A, K70AK219A) was not altered compared to the localization of
WT T7NS1A when co-expressed with SUMO1. For WT and all SUMOylation-deficient
mutants, there was substantial co-localization with Ubc9 in the nucleus, therefore
suggesting that SUMOylation does not play a substantial role in affecting the subcellular localization of T7NS1A.

3.12 Up-regulation or down-regulation of SUMOylation does not bear any effect
on localization of NS1A following infection:
Next, in order to ascertain if alteration in cellular SUMOylation level affects
NS1A’s

sub-cellular

distribution

following

infection,

recombinant

adenoviruses

engineered to produce well characterized effects on the cellular SUMOylation system
were used for transduction in A549 cells. To up-regulate cellular SUMOylation, a
recombinant adenovirus carrying the dicistronic SUMO1 construct (AdV-Dual S1/I/U)
was used. Similarly, to down-regulate SUMOylation, either the AdV-Dual S1ΔGG/I/U,
carrying the non-conjugatable diglycine deletion mutant known to produce a block in the
SUMOylation cascade, or the AdV-Dual Ubc9(C93S)/I/Ulp1, carrying an expression
cassette for both, a Ubc9 mutant lacking the SUMO conjugating activity, and the yeast
de-SUMOylating enzyme Ulp1, were used. 48 hrs post-transduction, cells were infected
with Influenza strain A/PR/8/34 H1N1 at a MOI of 0.5 and 10 hrs post-infection the cells
were fixed with 4% paraformaldehyde and prepared for immunofluorescence using an
anti-NS1A mouse monoclonal antibody as primary antibody and Alexa 488 Goat antimouse antibody as secondary antibody.

43

As of Figure 13, no major difference was observed in the localization of NS1A in
cells up-regulated or down-regulated in SUMOylation, in comparison to the control
infected samples where there was no adenoviral transduction or transduction with AdvLacZ, where there were no changes in SUMO level. In all the samples observed, NS1A
exhibited nuclear and cytoplasmic distribution, indicating that the alterations in the
SUMOylation system produced by transduction with different recombinant adenoviruses
did not affect the sub-cellular localization of NS1A expressed during infection.

3.13 SUMOylation does not seem to affect NS1A’s stability:
Among other numerous biological functions, SUMOylation is also known to alter
protein stability by two different mechanisms: 1) by working as a ubiquitin antagonist
competing with the ubiquitin system for modification of specific lysine residues; and, 2)
by enhancing the recognition by ubiquitin ligases able to recognize poly-SUMO2/3
chains. The first mechanism increases protein stability, whereas the second one
decreases it [26, 27, 61]. To investigate, whether SUMOylation affected the stability of
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NS1A, WT T7NS1A and its SUMOylation deficient double mutant T7NS1A-K70A/K219A
were over-expressed by transfection in HEK293A cells, and the cells were subsequently
treated with cycloheximide to stop overall protein synthesis. Samples collected at
different time points post-cycloheximide treatment were then analyzed by SDS-PAGE
and Western blotting.
Our data (shown in Figure 14) indicated that NS1A is a very stable protein and
that SUMOylation does not affect its stability in any obvious manner. Following
cycloheximide (CHX) treatment, both WT and mutant T7NS1A showed a similar timedependent decrease in protein levels, and in both cases the decrease was minimal
even at 12 hrs post CHX treatment, exhibiting cellular levels similar to those observed in
the untreated samples used as control. Altogether these observations indicated that
SUMOylation does not seem to affect NS1A’s protein stability.

3.14 The alternative spliced form of NS gene, NS2 (NEP) is also SUMO1-modified:
The 8th and last segment of vRNA segment of Influenza A virus encodes two
non-structural proteins, one unspliced form and one alternatively spliced form, [62]. The
alternative splicing of NS gene results into formation of a protein of 121 amino acid
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residues and approximately 14 kDa in size, known as NS2 [Figure 15A]. To determine if
NS2 is also targeted by SUMOylation a T7 tagged NS2 clone was constructed using
site-directed mutagenesis approach. Then, HEK293A cells were co-transfected with the
expression plasmid for T7-tagged NS2 and different combinations of other plasmids,
including Dual SUMO1/I/U, in the absence (-) and presence (+) of the SUMO deconjugating enzyme SENP1. Samples were collected and analyzed as before by
immunoblotting.
As shown in Figure 15, co-transfection with Dual SUMO1 led to the appearance
of a higher molecular weight form of T7NS2 [Figure 15B, lane 5], which disappeared in
the presence of SENP1 [Figure 15B, lane 6], demonstrating that NS2 is also modified
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by SUMO1 in mammalian cells. Overall SUMOylation level was revealed by SUMO1
antibody profile [Figure 15C], while GAPDH in Figure 15D confirmed equal loading in all
the samples. The data thus obtained unequivocally confirmed the SUMO modification of
NS2.

3.15 The artificial ligase, NS1A1-87_Ubc9 fusion, dramatically increases the
endogenous SUMOylation of NS1A:
As mentioned earlier, at any given point the SUMOylated form of a given protein
is only a very small fraction of its unmodified form [36, 37], thus studying the functional
consequences of SUMOylation of a given protein is fairly challenging. In order to
increase the endogenous SUMOylation of T7NS1A, an ‘artificial SUMO ligase’ was
developed by crafting a fusion of the RNA-binding domain of NS1A including the linker
region (NS1A1-87), with Ubc9. To this end, the coding region of Ubc9 was cloned
downstream of the NS1A1-87 ORF, generating the NS1A1-87_Ubc9 fusion. The ‘artificial
ligase’ idea was based on the fact that NS1A is well known to form dimers. If NS1A187_Ubc9

works appropriately as a ligase, it should increase the level of endogenous

SUMOylation of T7NS1A when co-transfected in mammalian cells. Furthermore,
according to the findings of this study, the major SUMOylation site in NS1A is K219,
thus the artificial ligase (NS1A1-87_Ubc9) should not be able to SUMOylate itself. To test
our hypothesis, HEK293A cells were co-transfected with NS1A1-87_Ubc9 fusion and
T7NS1A, in the absence (-) or presence (+) of the de-conjugating enzyme SENP1. As
positive control and to provide a model for comparison, co-transfection with Dual S1/I/U
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and T7NS1A was also performed. 24 hrs post-transfection, cell lysates were collected in
2X sample buffer and analyzed by SDS-PAGE and Western Blotting.
As shown in Figure 16, NS1A1-87_Ubc9 worked perfectly in its capacity as a
ligase, as it dramatically enhanced the level of endogenous SUMOylation of T7NS1A
[Figure 16A, Compare Lane 4 with Lane 3]. The level of SUMOylation achieved with
NS1A1-87_Ubc9 was even more than the level observed upon up-regulating cellular
SUMOylatiopn with the Dual S1/I/U construct. In the presence of SENP1, the amount of
SUMOylated form of T7NS1A was decreased but not abolished [Figure 16A, Lane 5],
contrary to the effect of SENP1 observed with Dual S1/I/U [Figure 16A, Lane 7],
indicating that NS1A1-87_Ubc9 fusion dramatically shifts the balance of the
SUMOylation-deSUMOylation

events

affecting

NS1A

toward

its

rapid

SUMO

conjugation, surpassing its de-conjugation, which is otherwise normally the predominant
event. Interestingly, over-expression of NS1A1-87_Ubc9 did not lead to the global
increase of cellular SUMOylation observed with Dual S1/I/U [Figure 16B], which suggest
that the effect observed is highly specific. Figure 16C demonstrated the level of
endogenous Ubc9 as well as the relative position of Dual S1/I/U and Ubc9 fused to
NS1A1-87, while Figure 16D confirmed equal loading in all different samples. Altogether
the data demonstrated that the NS1A1-87_Ubc9 is functioning adequately as a new
developed tool to specifically increase the endogenous level of SUMOylation without
altering the global SUMOylation pattern.
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3.16 Determining the specificity of NS1A1-87_Ubc9 fusion on SUMOylating a
substrate:
In order to further assess the specificity of the ‘artificial SUMO ligase’ described
above, we evaluated the SUMOylation of the SUMO-deficient mutants of T7NS1A. As
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the artificial ligase is increasing T7NS1A’s ability to be SUMOylated significantly, it was
needed to test if SUMOylation occurred at the previously mapped SUMOylation sites or
in other residues. To this end, HEK293A cells were transfected with the NS1A1-87_Ubc9
fusion together with WT and SUMOylation deficient mutants of T7NS1A, in the absence
(-) or presence (+) of SENP1. Cell lysates were collected 24 hrs post-transfection with
2X sample buffer and analyzed by SDS-PAFE followed by western blotting.
As shown in Figure 17, when the SUMOylation deficient mutants were used for
co-transfection, the level of SUMOylation mediated by the NS1A1-87_Ubc9 fusion was
dramatically reduced compared to the SUMOylation level of WT T7NS1A [Figure 17A,
Compare Lanes 6, 8 and 10 with Lane 4], indicating that the artificial ligase targeted its
substrate at the same lysine residues previously mapped as the main SUMOylation
sites in NS1A. Blotting with SUMO1 [Figure 17B] and SUMO2 [Figure 17C] again
confirmed that there was no global increase in overall SUMO conjugation in cells.
Immunoblotting directed against Ubc9 revealed the level of endogenous Ubc9 and
relative level of NS1A1-87_Ubc9, and the level of GAPDH established the loading control
of the experiment. Altogether, this experiment confirmed the specificity conferred by
NS1A1-87_Ubc9 fusion in SUMOylating a substrate at specific sites and provided a
powerful tool to enhance endogenous SUMOylation level of T7 tagged NS1A
specifically to help analyzing its biological role(s).
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CHAPTER 4: SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS
4.1 Summary and Conclusions:
Current anti-influenza weapons include annual vaccinations and antiviral drugs.
Such measures normally target structural components of the virus, thus are prone to
encounter viral resistance over relatively short time-span. Vaccination is a validated and
widely used option against influenza, but for immunocompromised patients its
effectiveness is minimal. In addition, the strain specific nature of the annual vaccine
limits its ability to hinder any new strain variant generated as a result of antigenic drift or
antigenic shift. Thus, the ever-changing nature of influenza virus constitutes the major
limiting factor for the effective prevention of influenza by vaccination. The major antiviral
drugs against influenza belong to two main groups, neuraminidase inhibitors
(Oseltamivir and Zanamivir) and M2 ion channel pump inhibitors (Adamantanes i. e.
Amantadine and Rimantadine) [1, 2]. Both types of drugs target structural components
of virus, and therefore are prone to favor the rapid selection of resistant viral strains
produced by the high mutation rate associated to the error-prone viral RdRp. In a recent
study, it was shown that a single spontaneously arising mutation in Neuraminidase
(H274Y) is responsible for the virtually 100% prevalence of Oseltamivir (TAMIFLU)resistant viruses among all H1N1 viral isolates characterized in the USA during the
2008-2009 influenza season [63]. So, the leading antiviral against influenza has lost its
effectiveness against seasonal influenza. Surprisingly, in a previous epidemiological
study it was observed that a single amino acid substitution affecting any one of five
amino acids in the transmembrane domain of M2 protein is capable of generating
Amantadine resistant strains of influenza A virus. Furthermore, the fitness of the
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resistant virus generated is equivalent with the wild-type (WT) virus [64]. While it was
previously demonstrated that during 2005-2006 influenza season, 90% of H3N2 viruses
and 15% of H1N1 viruses analyzed were resistant to Adamantanes [2], according to
CDC, the circulating H3N2 viruses analyzed during last influenza season of 2008-09
showed practically 100% resistance against Adamantanes [65].
From this perspective considering the potential drawbacks of available
measures, there is an urgent need for a more generalized approach to combat
influenza. One possible alternative is to target cellular systems either required for viral
growth or able to neutralize viral growth, which will be less prone to be affected by the
emergence of resistant viruses. Additionally to our advantage, targeting cellular systems
will be able to work irrespective of the type, strain and antigenic properties of the virus,
which will be quite advantageous considering the broad array of subtypes of influenza
virus. As the virus is dependent on the host cells for its multiplication, targeting the host
cellular factors essential for influenza infection may provide an attractive alternative for
antiviral therapy. The concept of inhibiting specific cellular functions, which are
indispensable for the virus for its efficient infection, but not required by the host cells for
short time period, has already been proposed as a way to limit the generation of
resistant viruses [66]. Though in recent years a wide variety of different antiviral
approaches have been explored, targeting cellular factors seems to have the most
promising outcome [67].
In recent studies, ISG15 conjugation to NS1A protein is reported as one of the
antiviral mechanisms mediated by host cells, therefore restricting viral replication by
some loss-of essential functions performed by this protein [21, 22]. On the contrary, it
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was shown previously that influenza virus also developed some mechanisms to
overcome host anti-interferon response as exemplified by NS1A targeting ubiquitin
ligase TRIM25, therefore inhibiting TRIM25 mediated ubiquitination of CARD domain of
RIG-I that is a viral RNA sensor and facilitator of type-I interferon production [68].
Altogether both examples establish an entire new arena of complex virus-host
interactions where post-translational modifications of the host cells play some important
roles in context to influenza infection, sometimes mediating an anti-viral response, or
being exploited by the virus to override the host defense.
Several lines of evidence already have established the fact that some DNA
viruses utilize the host SUMOylation machinery for producing optimal environment for
infection. SUMOylation also appears to facilitate infection by modulating activity or
localization of some of the viral proteins [41-44].
As mentioned by the recent genome-wide RNAi screening, SUMOylation
appears to be an important cellular factor required by influenza virus for its efficient
multiplication [51]. Our current study reveals that upon influenza infection the cellular
SUMOylation level is increased. From unpublished observations of our lab, it seems
SUMOylation promotes influenza infection as down-regulation of SUMOylation
precluded production of some viral proteins those are important for its efficient infectivity
or release of new virions. Along with those observations, as mentioned in this thesis,
there are more than one SUMO-modified proteins of influenza virus including NS1A that
serves as an important virulence factor and one of the main weapons of influenza virus
to counteract cellular defense. Though the underlying mechanism how SUMOylation is
able to advance viral infection remains elusive, altogether it is indicative that this post-
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translational modification may serve as an attractive target to impede influenza viral
infection in future.
Additionally, as mentioned before, NS1A was identified in this study as an
authentic target for SUMOylation system, even being modified with endogenous level of
SUMOylation present in cells. The mutagenesis study presented herein identified K219
of NS1A protein as the main SUMOylation site for both SUMO1 and SUMO2/3 while
K70A was recognized as the secondary site. Interestingly, a multiple sequence
alignment [Figure 18] form an array of different Influenza A virus subtypes identified
K219 as a totally conserved residue among all human subtypes, which is unanticipated
from such a variable virus. Some of strain-specific NS1A were truncated but ending on
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residue K219, signifying this residue plays some important roles for the virus.
Importantly, a recent study by Zhao et al. showed that recombinant viruses with a
substitution of K219R in NS1A could not be generated [21], and in the same study K219
was also shown as a secondary site for ISG15 modification, implying K219 as a very
crucial residue for the virus survivability as well.
Although the biological implications of SUMOylation for NS1A still remain elusive,
with the new “artificial SUMO ligase” approach generated in this study, it is possible to
enhance the level of endogenous SUMOylation of NS1A to a dramatic extent, which
essentially will help in analyzing the functional consequences of NS1A SUMOylation in
a protein-specific manner.
Collectively, this study extended the proposed interplay of influenza virus with the
cellular SUMOylation system, reporting several influenza viral proteins as SUMO targets
for the first time and casting insights on a new paradigm of virus-host interactions.

4.2 Future Directions:
To this point, influenza still remains as one of the oldest diseases with the
potential to cause major life threatening pandemics. The increasing resistance of the
viruses against the available antivirals necessitates development of novel generic
therapeutic approaches without the side effects of conferring resistance. The idea of
targeting cellular factors necessary for viral survival is gradually gaining popularity to
impede the progression of this disease. Along with other cellular factors, SUMOylation
appeared as a crucial factor necessary for efficient viral infection [51, 52]. Analyzing
how influenza virus interacts with the SUMOylation system and the consequences of
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this interplay may provide us with new tools to develop a broad spectrum antiviral
therapy. In this study, NS1A has also been identified as an authentic SUMO target
being modified primarily in a thoroughly conserved residue in all human influenza A
virus sub-types. It will be intriguing to analyze the possible roles played by SUMOylation
for the multifunctional protein NS1A in order to further understand the virus-host
interactions and find new approaches to hinder some essential functions performed by
this protein to help the virus evade the cellular defense mechanisms. Though the
precise mechanism of functional consequences of SUMOylation for NS1A is still
undefined, the accumulating evidence suggests that exploring this new arena will shed
lights in the process of developing and designing novel prevention strategy against
influenza virus.
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